Volition is a multinational epigenetics company that develops blood-based diagnostic tests for early detection and monitoring of cancers and diseases associated with NETosis, such as sepsis. The company leverages proprietary technologies, including its Nucleosome Quantification (Nu.Q®) platform and Capture-PCR/Capture-Seq liquid biopsy approaches, that analyze chromosomal structures as biomarkers to detect characteristic disease changes from early stages. Volition monetizes its intellectual property through a licensing and partnership model with major diagnostics companies like Werfen, Hologic, and Revvity in the human market, while also commercializing veterinary cancer screening products through distributors such as IDEXX and Antech; the company generates revenue from upfront and milestone payments, royalties, product kit sales, and direct diagnostic services across human and veterinary segments.